Jay T Flatley

Omid spent 15 years across Illumina and its predecessor sequencing company, Celexa, helping guide the companies during the rise of next generation sequencing and the genomics revolution that transformed biological research and clinical diagnostics.

Along the way, he worked alongside industry pioneers, including Jay Flatley and Mustafa Ranagi, gaining a front row seat to how breakthrough technologies became category-defining businesses.

Today, he leads Selenome, a company founded on the idea that while genomics has taught us a tremendous amount about biology, many of the most important questions still require understanding what living cells actually do.

Selenome has developed a platform that combines live cell imaging, AI-driven analysis, and single-cell molecular profiling to follow cells over time and link cellular behavior with molecular state.

And if you then think about the importance of understanding the fundamentals of not only neurobiology, but its interaction with the immune system, like if you think about the range of diseases that we want to better understand and address, whether it's Alzheimer's or Parkinson's or you name it, This is an avenue through which we think people are going to be able to gain the type of insights that we believe in time are going to accelerate understanding of the biology and in due course our ability to be able to affect it.

Excellent.

So you worked closely with Jay Flatley during Illumina's rise.

I wanted to ask a question on leadership.

2006.

I got my final interview with Jay Flatley and Christian Henry.

And, you know, as a young kid, you know, looking for his first job outside of academics.

It was fun, but I'd gotten to know them.